Evidence map›Paper›PMID 34685650›Full record

ArticleCells2021

The Use of Human Serum Samples to Study Malignant Transformation: A Pilot Study.

Andreana N Holowatyj, Biljana Gigic, Christy A Warby, Jennifer Ose, Tengda Lin, Petra Schrotz-King, Cornelia M Ulrich, Jamie J Bernard

Registry-linked trialAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02328677 (ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02328677 recruitingnot on this map

ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis

TypeobservationalSponsorUniversity of UtahRan2007 to 2030Enrolled5,000ConditionsColorectal Cancer
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andreana N HolowatyjDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-8001-8793
Biljana GigicDepartment of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0002-8085-2072
Christy A WarbyHuntsman Cancer Institute, Salt Lake City, UT 84112, USA.
Jennifer OseHuntsman Cancer Institute, Salt Lake City, UT 84112, USA.ORCID 0000-0002-2030-9676
Tengda LinHuntsman Cancer Institute, Salt Lake City, UT 84112, USA.
Petra Schrotz-KingGerman Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0003-4339-3492
Cornelia M UlrichHuntsman Cancer Institute, Salt Lake City, UT 84112, USA.ORCID 0000-0001-7641-059X
Jamie J BernardDepartment of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48823, USA.

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI CORNELIA M ULRICH · 1986 to 2026
$72.6M
Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare StudyU01CA206110 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jane C. Figueiredo, Christopher I Li · 2016 to 2026
$18.6M
Building Interdisciplinary Research Careers in Women's HealthK12HD043483 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARTMANN, KATHERINE E, MAJOR, AMY S · 2002 to 2023
$10.3M
Discovery and verification of novel biomarkers of colorectal cancer recurrenceR01CA189184 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2015 to 2020
$5.6M
Metabolomic Strategies for Discovery and Validation of Biomarkers of Colorectal Cancer RecurrenceR01CA207371 · NCI · UNIVERSITY OF UTAH · PI LI, CHRISTOPHER I, ULRICH, CORNELIA M · 2017 to 2022
$3.9M
Mechanistic role of obesity in benzo(a)pyrene-initiated cancerR01ES030695 · NIEHS · MICHIGAN STATE UNIVERSITY · PI BERNARD, JAMIE J · 2020 to 2023
$1.5M
The Role of Fat in Tumor FormationR00CA177868 · NCI · MICHIGAN STATE UNIVERSITY · PI BERNARD, JAMIE J · 2015 to 2017
$699k
The Role of Fat in Tumor FormationK99CA177868 · NCI · RUTGERS, THE STATE UNIV OF N.J. · PI BERNARD, JAMIE J · 2014 to 2014
$89k
NCATS NIH HHS UL1 TR002538NCI NIH HHS K99 CA177868NCI NIH HHS P30 CA042014NCI NIH HHS R00 CA177868NCI NIH HHS R01 CA189184NCI NIH HHS R01 CA207371NCI NIH HHS U01 CA206110NICHD NIH HHS K12 HD043483NIEHS NIH HHS R01 ES030695
6 · The paper itself

Abstract

Obesity and excess adiposity account for approximately 20% of all cancer cases; however, biomarkers of risk remain to be elucidated. While fibroblast growth factor-2 (FGF2) is emerging as an attractive candidate biomarker for visceral adipose tissue mass, the role of circulating FGF2 in malignant transformation remains unknown. Moreover, functional assays for biomarker discovery are limited. We sought to determine if human serum could stimulate the 3D growth of a non-tumorigenic cell line. This type of anchorage-independent 3D growth in soft agar is a surrogate marker for acquired tumorigenicity of cell lines. We found that human serum from cancer-free men and women has the potential to stimulate growth in soft agar of non-tumorigenic epithelial JB6 P

Indexed as

AgedCell Transformation, NeoplasticFemaleFibroblast Growth Factor 2HumansMaleMiddle AgedPilot ProjectsReceptor, Fibroblast Growth Factor, Type 1SerumFibroblast Growth Factor 2Receptor, Fibroblast Growth Factor, Type 1body fatnessbody mass indexFGF2obesityoverweight

Identifiers

PMID34685650
PMCPMC8534413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.